Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


A substantial proportion of children <12 months of age develop measles in both endemic and epidemic situations. Studies in African children indicate that the AIK-C measles vaccine is more immunogenic than Schwartz vaccine in children <12 mo., with persistent maternal antibody.

U.S. infants (368) were equally randomized to receive, at 6 months of age: 1) AIK-C vaccine (Pasteur Merieux, France, 3.9 log10 TCID50); 2) Moraten vaccine (Merck, ≥3 log10 TCID50); or placebo. Measles antibody titers were measured by hemagglutination inhibition (HI) and plaque neutralization (PN) on pre-vaccination and 2 month post-vaccination sera. Titers were converted to mIU/ml by use of WHO standard. Serum immune responses of the first 266 children follow: Table There were NS differences in seroresponses to the 2 vaccines at 6 months of age. Serum immune responses to MMR vaccination at 12 months and antibody persistence at 24 mo. will be measured.

Table 1

We conclude that 2 mo. post-immunization there is no apparent immunological advantage of using AIK-C, in place of Moraten, for 6 month old U.S. children. Funded by Pasteur Merieux Connaught.

Author information



Rights and permissions

Reprints and Permissions

About this article

Cite this article

Rennels, M., Rothstein, E., Jefferson, T. et al. AIK-C AND MORATEN MEASLES VACCINE AT AGE 6 MONTHS. • 756. Pediatr Res 41, 128 (1997).

Download citation


Quick links